Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 17, 2024

Press releases

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Apr 2, 2024

Press releases

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 27, 2024

Press releases

Evaxion Announces Business Update and Full Year 2023 Financial Results

Evaxion today provides a business update and announces full year 2023 financial results.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Mar 19, 2024

Press releases

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.

R&D Day on AI-Immunology™ March 19, 2024

Mar 19, 2024

Presentations

R&D Day on AI-Immunology™ March 19, 2024

Take a look at the presentations from our Research & Development (R&D) Day on AI-Immunology™ captured in a series of videos. 

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 29, 2024

Press releases

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Feb 20, 2024

Press releases

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 7, 2024

Press releases

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion announces that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Feb 1, 2024

Press releases

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Evaxion announces the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Jan 24, 2024

Press releases

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Evaxion announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).

Evaxion Announces Completion of ADS Ratio Change

Jan 22, 2024

Press releases

Evaxion Announces Completion of ADS Ratio Change

Evaxion today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.

BioStock Interview with CEO Christian Kanstrup

Jan 9, 2024

Presentations

BioStock Interview with CEO Christian Kanstrup

In this interview with BioStock, our CEO, Christian Kanstrup, discusses his vision for Evaxion, delving into AI, cancer, and partnerships.

Evaxion Media kit

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.